Evidence map›Paper›PMID 25054045›Full record

ArticleMolecular and clinical oncology2014

Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma.

Michael Schmitt, Rudolf Trenschel, Herbert G Sayer, Catarina Schneider, Aenne Glass, Inken Hilgendorf, Anne Treschl, Christian Junghanss, Kersten Borchert, Michael Koenigsmann and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Michael SchmittDepartment of Internal Medicine III, University of Rostock, Rostock D-18057, Germany ; Department of Internal Medicine V, University of Heidelberg, Heidelberg D-69120, Germany.
Rudolf TrenschelDepartment of Bone Marrow Transplantation, University of Duisburg-Essen, Essen D-45147, Germany.
Herbert G SayerDepartment of Hematology and Oncology, University of Jena, Jena D-07747, Germany.
Catarina SchneiderDepartment of Internal Medicine III, University of Rostock, Rostock D-18057, Germany.
Aenne GlassInstitute for Biostatistics and Informatics in Medicine and Ageing Research, University of Rostock, Rostock D-18057, Germany.
Inken HilgendorfDepartment of Internal Medicine III, University of Rostock, Rostock D-18057, Germany.
Anne TreschlDepartment of Hematology and Oncology, University of Jena, Jena D-07747, Germany.
Christian JunghanssDepartment of Internal Medicine III, University of Rostock, Rostock D-18057, Germany.
Kersten BorchertDepartment of Internal Medicine III, University of Rostock, Rostock D-18057, Germany.
Michael KoenigsmannDepartment of Hematology and Oncology, University of Magdeburg, Magdeburg D-39120, Germany ; Hematology and Oncology Practice, Hannover D-30171, Germany.
Jochen CasperDepartment of Internal Medicine III, University of Rostock, Rostock D-18057, Germany ; Department of Oncology and Hematology, Oldenburg Hospital, Oldenburg D-26133, Germany.
Dietrich W BeelenDepartment of Bone Marrow Transplantation, University of Duisburg-Essen, Essen D-45147, Germany.
Mathias FreundDepartment of Internal Medicine III, University of Rostock, Rostock D-18057, Germany.
Christoph KahlDepartment of Internal Medicine III, University of Rostock, Rostock D-18057, Germany ; Magdeburg Hospital, Magdeburg D-39130, Germany.
University of Rostock · DEUniversity of Duisburg-Essen · DEUniversity Hospital Magdeburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of refractory or relapsed non-Hodgkin lymphoma (NHL) remains challenging. In this retrospective study, 88 patients with refractory or relapsed NHL received treosulfan and fludarabine as a reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Of the 88 intensely pre-treated patients, 73 experienced a relapse, with 18 of the 88 patients experiencing an early relapse (ER; <6 months from the last chemotherapy). At the time of allo-HSCT, 26 patients were in complete remission (CR) and 43 in partial remission (PR), 12 patients had progressive disease (PD) and 7 had stable disease (SD). A total of 47 patients received an autologous graft followed by allo-HSCT. Following allo-HSCT, 69 of the 88 patients were in CR and 7 were in PR, resulting in an overall response rate of 86.4% (76/88). A total of 33 patients achieved a CR from PR, as did 6 patients from PD and 5 from SD. Of the 88 patients, 43 (49%) were alive at the end of the follow-up period. The patients who directly underwent allo-HSCT without prior auto-HSCT exhibited a better disease-free survival (DFS; P=0.038) with a tendency (P=0.077) for a better overall survival (OS). The patients with ER exhibited a probability of OS of 0.35±0.12 after 3 and 7 years. Chronic graft-versus-host disease (cGvHD) exerted a positive effect on OS and DFS (for limited cGvHD vs. no cGvHD, P=0.002 and 0.004, respectively). In conclusion, allogeneic stem cell transplantation following conditioning with treosufan and fludarabine constitutes a viable therapeutic option for patients with refractory or relapsed NHL and should be considered early during the course of salvage treatment.

Indexed as

conditioningnon-Hodgkin lymphomatransplantationtreosulfan

Identifiers

PMID25054045
PMCPMC4106739
OpenAlexW1963609590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.